Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Heartseed, Inc. ( (JP:219A) ) has shared an announcement.
Heartseed Inc. announced the termination of its exclusive worldwide collaboration and license agreement with Novo Nordisk A/S, as Novo Nordisk shifts focus to its core business areas. The termination impacts Heartseed’s overseas business strategy and intellectual property management, but does not affect its ongoing clinical trials or technology development. The company will now receive 100% of sales revenue in Japan and plans to continue its development efforts domestically while exploring new overseas partnerships.
The most recent analyst rating on (JP:219A) stock is a Hold with a Yen3290.00 price target. To see the full list of analyst forecasts on Heartseed, Inc. stock, see the JP:219A Stock Forecast page.
More about Heartseed, Inc.
Heartseed Inc. operates in the biotechnology industry, focusing on cardiac remuscularization therapy. The company develops therapeutic programs for heart failure patients using allogeneic iPS cell-derived cardiomyocytes spheroids, with a market focus on Japan and potential overseas expansion.
Average Trading Volume: 861,001
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen71.95B
Learn more about 219A stock on TipRanks’ Stock Analysis page.